Log in

NASDAQ:ADMSAdamas Pharmaceuticals Stock Price, Forecast & News

+0.34 (+12.88 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $2.98
50-Day Range
MA: $3.02
52-Week Range
Now: $2.98
Volume1.72 million shs
Average Volume462,519 shs
Market Capitalization$83.92 million
P/E RatioN/A
Dividend YieldN/A
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Read More
Adamas Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ADMS



Sales & Book Value

Annual Sales$54.64 million
Book Value($0.03) per share


Net Income$-105,190,000.00
Net Margins-160.44%


Market Cap$83.92 million
Next Earnings Date8/13/2020 (Estimated)

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

How has Adamas Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADMS stock has decreased by 2.3% and is now trading at $2.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Adamas Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Adamas Pharmaceuticals.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Adamas Pharmaceuticals.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) released its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.18. The specialty pharmaceutical company earned $14.48 million during the quarter, compared to analysts' expectations of $15.07 million. Adamas Pharmaceuticals had a negative net margin of 160.44% and a negative return on equity of 806.54%. View Adamas Pharmaceuticals' earnings history.

What price target have analysts set for ADMS?

9 analysts have issued 1 year price objectives for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $16.14 in the next twelve months. This suggests a possible upside of 441.7% from the stock's current price. View analysts' price targets for Adamas Pharmaceuticals.

Has Adamas Pharmaceuticals been receiving favorable news coverage?

Media headlines about ADMS stock have trended somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutAdamas Pharmaceuticals.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 1,070,000 shares, a decrease of 10.8% from the April 15th total of 1,200,000 shares. Based on an average daily trading volume, of 343,800 shares, the days-to-cover ratio is currently 3.1 days. Approximately 4.8% of the shares of the stock are short sold. View Adamas Pharmaceuticals' Current Options Chain.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.32%), Stonepine Capital Management LLC (4.13%), Emerald Mutual Fund Advisers Trust (2.12%), Morgan Stanley (1.83%), Nuveen Asset Management LLC (1.71%) and State Street Corp (1.57%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes and Richard King. View institutional ownership trends for Adamas Pharmaceuticals.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Bingham Osborn & Scarborough LLC, Deutsche Bank AG, DCF Advisers LLC, GSA Capital Partners LLP, UBS Group AG, and Geode Capital Management LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, and Jennifer J Rhodes. View insider buying and selling activity for Adamas Pharmaceuticals.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, AQR Capital Management LLC, JPMorgan Chase & Co., BlackRock Inc., Emerald Mutual Fund Advisers Trust, Nuveen Asset Management LLC, State Street Corp, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $2.98.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $83.92 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.